Substances Prohibited At All Times

If a Substance or Method is not defined in this list, please verify with your Anti-Doping Organization.

Expand All Collapse All
  • S0. Non-Approved Substances

  • Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited.
  • S1. Anabolic Agents

  • Anabolic agents are prohibited.

    1. Anabolic Androgenic Steroids (AAS)

    a. Exogenous* AAS, including:

    • 1-androstenediol (5α-androst-1-ene-3β,17β-diol)
    • 1-androstenedione (5α-androst-1-ene-3,17-dione)
    • bolandiol (estr-4-ene-3β,17β-diol)
    • bolasterone
    • boldenone
    • boldione (androsta-1,4-diene-3,17-dione)
    • calusterone
    • clostebol
    • danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol)
    • dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
    • desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol)
    • drostanolone
    • ethylestrenol (19-norpregna-4-en-17α-ol)
    • fluoxymesterone
    • formebolone
    • furazabol (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol)
    • gestrinone
    • 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one)
    • mestanolone
    • mesterolone
    • metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
    • metenolone
    • methandriol
    • methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one)
    • methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one)
    • methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one)
    • methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one)
    • methyltestosterone
    • metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one)
    • mibolerone
    • nandrolone
    • 19-norandrostenedione (estr-4-ene-3,17-dione)
    • norboletone
    • norclostebol
    • norethandrolone
    • oxabolone
    • oxandrolone
    • oxymesterone
    • oxymetholone
    • prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α-androstane)
    • quinbolone
    • stanozolol
    • stenbolone
    • 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one)
    • tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one)
    • trenbolone (17β-hydroxyestr-4,9,11-trien-3-one)
    • and other substances with a similar chemical structure or similar biological effect(s).

    b. Endogenous** AAS when administered exogenously:

    • androstenediol (androst-5-ene-3β,17β-diol)
    • androstenedione (androst-4-ene-3,17-dione)
    • dihydrotestosterone (17β-hydroxy-5α-androstan-3-one)
    • prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one)
    • testosterone
    and their metabolites and isomers, including but not limited to:
    • 5α-androstane-3α,17α-diol
    • 5α-androstane-3α,17β-diol
    • 5α-androstane-3β,17α-diol
    • 5α-androstane-3β,17β-diol
    • androst-4-ene-3α,17α-diol
    • androst-4-ene-3α,17β-diol
    • androst-4-ene-3β,17α-diol
    • androst-5-ene-3α,17α-diol
    • androst-5-ene-3α,17β-diol
    • androst-5-ene-3β,17α-diol
    • 4-androstenediol (androst-4-ene-3β,17β-diol)
    • 5-androstenedione (androst-5-ene-3,17-dione)
    • epi-dihydrotestosterone
    • epitestosterone
    • etiocholanolone
    • 3α-hydroxy-5α-androstan-17-one
    • 3β-hydroxy-5α-androstan-17-one
    • 7α-hydroxy-DHEA
    • 7β-hydroxy-DHEA
    • 7-keto-DHEA
    • 19-norandrosterone
    • 19-noretiocholanolone.

    2. Other Anabolic Agents, including but not limited to:

    • clenbuterol
    • selective androgen receptor modulators (SARMs)
    • tibolone
    • zeranol
    • zilpaterol.
    For purposes of this section:
    * “exogenous” refers to a substance which is not ordinarily produced by the body naturally.
    ** “endogenous” refers to a substance which is ordinarily produced by the body naturally.

    Notes

    For purposes of this section:
    * “exogenous” refers to a substance which is not ordinarily produced by the body naturally.

    ** “endogenous” refers to a substance which is ordinarily produced by the body naturally.

  • S3. Beta-2 Agonists

  • All beta-2 agonists, including all optical isomers (e.g. d- and l-) where relevant, are prohibited except inhaled salbutamol (maximum 1600 micrograms over 24 hours), inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regimen.

    The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.

  • S4. Hormone and Metabolic Modulators

  • The following are prohibited:

    1. Aromatase inhibitors including, but not limited to:

    • aminoglutethimide
    • anastrozole
    • androsta-1,4,6-triene-3,17-dione (androstatrienedione)
    • 4-androstene-3,6,17 trione (6-oxo)
    • exemestane
    • formestane
    • letrozole
    • testolactone.

    2. Selective estrogen receptor modulators (SERMs) including, but not limited to:

    • raloxifene
    • tamoxifen
    • toremifene.

    3. Other anti-estrogenic substances including, but not limited to:

    • clomiphene
    • cyclofenil
    • fulvestrant.

    4. Agents modifying myostatin function(s) including, but not limited, to:

    • myostatin inhibitors.

    5. Metabolic modulators:

    • Insulins
    • Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW 1516), PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR)
  • S5. Diuretics and Other Masking Agents

  • Masking agents are prohibited. They include:

    • diuretics
    • desmopressin
    • plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol)
    • probenecid
    • and other substances with similar biological effect(s).
    Local administration of felypressin in dental anaesthesia is not prohibited.

    Diuretics include:

    • acetazolamide
    • amiloride
    • bumetanide
    • canrenone
    • chlortalidone
    • etacrynic acid
    • furosemide
    • indapamide
    • metolazone
    • spironolactone
    • thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide)
    • triamterene
    • vaptans (e.g. tolvaptan)
    • and other substances with a similar chemical structure or similar biological effect(s) (except drospirenone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited).
    The use In- and Out-of-Competition, as applicable, of any quantity of a substance subject to threshold limits (i.e. formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the deliverance of a specific Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or other masking agent.

If a Substance or Method is not found, please verify with your Anti-Doping Organization to ensure that this Substance or Method is not prohibited as a related Substance or Method that falls under an existing category.

In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3.